Search

Your search keyword '"Emanuela Dell'Aquila"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Emanuela Dell'Aquila" Remove constraint Author: "Emanuela Dell'Aquila"
81 results on '"Emanuela Dell'Aquila"'

Search Results

1. Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer

3. Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study

4. Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group

5. Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients

6. Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis

7. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

8. Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

9. Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

11. Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study

12. Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis

13. Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study

14. Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group

15. Chemotherapy Rechallenge or Reintroduction, Regorafenib and Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A PROpensity ScorE Analysis of Treatment Beyond Second Line (PROSERpYNa Study)

16. Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, 'Real-Life', Case-Control Study

17. Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis

18. Facing SARS-CoV-2 outbreak in immunotherapy era

19. Comparative Analysis of Regorafenib and Trifluridine/Tipiracil in Later-Line Refractory Metastatic Colorectal Cancer: A Real-Life Multicenter Retrospective Study

20. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?

21. CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer

22. Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity

23. Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial

24. Clinical utility of plasma KRAS, NRAS and BRAF mutational analysis with real time PCR in metastatic colorectal cancer patients -The importance of tissue/plasma discordant cases

25. Efficacy of pembrolizumab in lung adenocarcinoma harboring non-V600E BRAF mutation: a case report

26. Synaptophysin expression in

27. Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer

28. COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

29. Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

30. Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter 'SLAVE' Study

31. Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

32. Denosumab for cancer-related bone loss

33. Liquid biopsy and tumor heterogeneity in metastatic solid tumors. The potentiality of blood samples

34. The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference

35. P-42 Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies as treatment option in vulnerable older patients with metastatic colorectal cancer: A retrospective cohort study

36. P-168 Second-line, anti-VEGF based after first-line, anti-EGFR based treatment in RAS wild-type metastatic colorectal cancer: The multicenter, retrospective, real-life SLAVE study

37. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis

38. A validated prognostic classifier for

39. Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer

40. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab. a real-life multicentre study

41. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

42. Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis

43. A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy

44. A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer : the ‘BRAF BeCool’ study

45. Aprepitant plus palonosetron as salvage therapy for CINV induced by moderately emetogenic chemotherapy in cancer patients

46. P-217 Value of liquid biopsy using high-affinity plasma DNA binding magnetic beads and qualitative real-time PCR for KRAS, NRAS and BRAF mutations in metastatic colorectal cancer patients

47. P-161 Efficacy of third-line anti-EGFR-based treatment versus regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients

48. P-348 A multi-institutional retrospective study of stage I-IV transverse colon cancer: Diagnosis, treatment and outcome analyses

49. Efficacy of third-line anti-EGFR-based treatment (tx) versus (vs) Regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts)

50. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Catalog

Books, media, physical & digital resources